Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-25T20:58:57.508Z Has data issue: false hasContentIssue false
  • English
  • Français

Recent Findings and Current Status of Augmentation Strategies

Published online by Cambridge University Press:  07 November 2014

Get access Rights & Permissions [Opens in a new window]

Extract

Augmentation strategies have become popular in patients with a partial response or residual symptoms. In a survey conducted by the American Society of Consultant Pharmacists, 65% of 169 psychiatrists indicated that they would augment treatment as the next step in a partial responder in contrast to non-responders in whom they would switch to another drug (J.C. Nelson, unpublished data). This decision is based on common sense and practicality rather than empirical evidence. Many clinicians and patients think that if a patient achieves at least a partial response to a medication, it makes sense to continue that drug and add a second. To some extent, the patient preferences for treatment shown in the Systematic Treatment Alternatives to Relieve Depression (STAR*D) study reflect this approach. This discussion will update clinicians on the use of augmentation agents for the treatment of major depressive disorder (MDD).

Lithium augmentation has been used since it was first described by de Montigny and colleagues in 1981. This strategy is based on a rational neurochemical hypothesis that lithium has a synergistic effect when added to a tricyclic antidepressant (TCA). Lithium increases serotonin turnover and the TCA increases postsynaptic serotonin receptor sensitivity. Recent debates have focused on whether lithium is as effective combined with selective serotonin reuptake inhibitors (SSRIs) as it is combined with a TCA. The rapid effects sometimes observed with lithium augmentation of TCAs does not seem to occur with SSRIs, conceivably because SSRIs do not increase postsynaptic serotonin receptor sensitivity.

Type
Expert Roundtable Supplement
Information
CNS Spectrums , Volume 12 , Issue S22: Augmentation Strategies in the Treatment of Major Depressive Disorder , December 2007 , pp. 6 - 9
Copyright
Copyright © Cambridge University Press 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Rush, AJ, Trivedi, MH, Wisniewski, SR, et al.Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905–1917.CrossRefGoogle ScholarPubMed
2.Dé Montigny, C, Grunberg, F, Mayer, A, Deschenes, JP. Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. Br J Psychiatry. 1981;138:252–256.CrossRefGoogle ScholarPubMed
3.Nelson, JC. Lithium augmentation in refractory depression. In: Roose, SP, Glassman, AH. Treatment Strategies for Refractory Depression. Washington, DC: American Psychiatric Press, Inc; 1990:35–49.Google Scholar
4.Crossley, NA, Bauer, M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry. 2007;68:935–940.CrossRefGoogle ScholarPubMed
5.Nierertberg, AA, Fava, M, Trivedi, MH, et al.A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry. 2006;163(9):1519–1530.CrossRefGoogle Scholar
6.Nierenberg, AA, Papakostas, GI, Petersen, T, et al.Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. J Clin Psychopharmacol. 2003;23:92–95.CrossRefGoogle ScholarPubMed
7.Nelson, JC, Mazure, C. Lithium augmentation in psychotic depression refractory to combined drug treatment. Am J Psychiatry. 1986;143:363–366.Google ScholarPubMed
8.Altshuler, LL, Bauer, M, Frye, MA. et al.Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am J Psychiatry. 2001;158(10):1617–1622.CrossRefGoogle ScholarPubMed
9.Posternak, M, Novak, S, Stern, R, et al.A pilot effectiveness study: placebo-controlled trial of adjunctive L-triiodothyronine (T3) used to accelerate and potentiate the antidepressant response. Int J Neuropsychopharmacol. 2007;13:1–11.Google Scholar
10.Cooper-Kazaz, R, Apter, JT, Cohen, R, et al.Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry. 2007;64:679–688.CrossRefGoogle ScholarPubMed
11.Aronson, R, Offman, HJ, Joffe, RT, Naylor, CD. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry. 1996;53(9):842–848.CrossRefGoogle ScholarPubMed
12.Gitlin, MJ, Weiner, H, Fairbanks, L, Hershman, JM, Friedfeld, N. Failure of T3 to potentiate tricyclic antidepressant response. J Affect Disord. 1987;13(3):267–272.CrossRefGoogle ScholarPubMed
13.Goodwin, FK, Prange, AJ Jr, Post, RM, Muscettola, G, Lipton, MA. Potentiation of antidepressant effects by L-triiodothyronine in tricyclic nonresponders. Am J Psychiatry. 1982;139(1):34–38.Google ScholarPubMed
14.Joffe, RT, Singer, W, Levitt, AJ, MacDonald, C. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry. 1993;50:387–393.CrossRefGoogle ScholarPubMed
15.Nelson, JC. Augmentation strategies in depression 2000. J Clin Psychiatry. 2000;61(suppl 2):13–19.Google ScholarPubMed
16.Patkar, AA, Masand, PS, Pae, CU, et al.A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. J Clin Psychopharmacol. 2006;26(6):653–656.CrossRefGoogle ScholarPubMed
17.Fava, M, Thase, ME, DeBattista, C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry. 2005;66(1):85–93.CrossRefGoogle ScholarPubMed
18.Thase, ME, Fava, M, DeBattista, C, Arora, S, Hughes, RJ. Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study. CNS Spectr. 2006;11(2):93–102.CrossRefGoogle ScholarPubMed
19.Jacobsen, FM. Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry. 1991;52:217–220.Google ScholarPubMed
20.Bakish, D. Fluoxetine potentiation by buspirone: Three case histories. Can J Psychiatry. 1991;36:749–750.CrossRefGoogle ScholarPubMed
21.Landén, M, Björling, G, Agren, H, Fahlén, T. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatmentrefractory depression. J Clin Psychiatry. 1998;59(12):664–668.CrossRefGoogle ScholarPubMed
22.Pérez, V, Soler, J, Puigdemont, D, Alvarez, E, Artigas, F, Grup de Recerca en Trastorns Afectius. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Arch Gen Psychiatry. 1999;56(4):375–379.CrossRefGoogle ScholarPubMed
23.Gabriel, A. Lamotrigine adjunctive treatment in resistant unipolar depression: an open, descriptive study. Depress Anxiety. 2006;23:485–488.CrossRefGoogle ScholarPubMed
24.Gutierrez, RL, McKercher, RM, Galea, J, Jamison, KL. Lamotrigine augmentation strategy for patients with treatment-resistant depression. CNS Spectr. 2005;10:800–805.CrossRefGoogle ScholarPubMed
25.Barbee, JG, Jamhour, NJ. Lamotrigine as an augmentation agent in treatment-resistant depression. J Clin Psychiatry. 2002;63:737–741.CrossRefGoogle ScholarPubMed
26.Barbosa, L, Berk, M, Vorster, M. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry. 2003;64:403–407.CrossRefGoogle ScholarPubMed
27.Seidman, SN, Rabkin, JG. Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression. J Affect Disord. 1998;48:157–161.CrossRefGoogle ScholarPubMed
28.Pope, HG, Cohane, GH, Kanayama, G, et al.Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am J Psychiatry. 2003;160:105–111.CrossRefGoogle ScholarPubMed
29.Orengo, CA, Fullerton, L, Kunik, ME. Safety and efficacy of testosterone gel 1% augmentation in depressed men with partial response to antidepressant therapy. J Geriatr Psychiatry Neurol. 2005;18:20–24.CrossRefGoogle ScholarPubMed
30.Seidman, SN, Miyazaki, M, Roose, SP. Intramuscular testosterone supplementation to selective serotonin reuptake inhibitor in treatment-resistant depressed men: randomized placebo-controlled clinical trial. J Clin Psychopharmacol. 2005;25:584–588.CrossRefGoogle ScholarPubMed
31.Schneider, LS, Small, GW, Hamilton, SH, et al.Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Fluoxetine Collaborative Study Group. Am J Geriatr Psychiatry. 1997;5:97–106.CrossRefGoogle Scholar
32.Schneider, LS, Small, GW, Clary, CM. Estrogen replacement therapy and antidepressant response to sertraline in older depressed women. Am J Geriatr Psychiatry. 2001;9:393–399.CrossRefGoogle ScholarPubMed
33.Morgan, ML. Cook, IA, Rapkin, AJ, Leuchter, AF. Estrogen augmentation of antidepressant in perimenopausal depression: a pilot study. J Clin Psychiatry. 2005;66:774–780.CrossRefGoogle ScholarPubMed
34.Rasgon, NL, Altshuler, LL, Fairbanks, LA, et al.Estrogen replacement therapy in the treatment of major depressive disorder in perimenopausal women. J Clin Psychiatry. 2002;63(suppl 7):45–48.Google ScholarPubMed
35.Dias, RS, Kerr-Correa, F, Moreno, RA, et al.Efficacy of hormone therapy with and without methyltestosterone augmentation ov venlafaxine in the treatment of postmenopausal depression: a double-blind controlled pilot study. Menopause. 2006;13:202–211.CrossRefGoogle Scholar
36.Papakostas, GI, Petersen, T, Mischoulon, D, et al.Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 1: predictors of clinical response in fluoxetine-reistant depression. J Clin Psychiatry. 2004;65:1090–1095.CrossRefGoogle ScholarPubMed
37.Coppen, A, Bailey, J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J Affect Disord. 2000;60(2):121–130.CrossRefGoogle ScholarPubMed